Phase 2 Completed N=60 Randomized Triple-blind Treatment

An Alternative Dosing Schedule of Varenicline for Smoking Cessation

Smoking Cessation

Source: ClinicalTrials.gov NCT00835900 ↗

Enrolled (actual)

Serious AEs

1.7%

Results posted

May 2017

Primary outcomePrimary: Change in Smoking Behavior — -6.3; -3.2 Change in Cigarettes Per Day

Summary

The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Smoking Behavior	-6.3; -3.2	—
SECONDARY Rates of Smoking Cessation.	17; 11	—

Eligibility Criteria

Inclusion Criteria

currently smoking at least 15 cigarettes daily
in good health
able to read and speak English fluently
have a home telephone and plan to reside in Western New York for 6 months
willing to make quit attempt
signed informed consent
who planned quit attempt.

Exclusion Criteria

serious medical condition
depression or mental health condition requiring treatment in the past year
history of panic disorder, psychosis, bipolar disorder
alcohol or drug abuse in the past year
use of tobacco products other than cigarettes
current use of other cessation pharmacotherapies
pregnancy/planned pregnancy.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00835900). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.